Shamim Ruff - 28 Jul 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC

Role
Director
Signature
/s/ Tracy Herson, attorney-in-fact
Issuer symbol
N/A
Transactions as of
28 Jul 2023
Net transactions value
-$595,620
Form type
4
Filing time
01 Aug 2023, 16:41:54 UTC
Previous filing
09 Jun 2023
Next filing
26 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Options Exercise $115,250 +1,250 +17% $92.20 8,609 28 Jul 2023 Direct
transaction RETA Class A common stock Options Exercise $614,605 +6,666 +77% $92.20 15,275 28 Jul 2023 Direct
transaction RETA Class A common stock Options Exercise $29,412 +319 +2.1% $92.20 15,594 28 Jul 2023 Direct
transaction RETA Class A common stock Sale $1,354,887 -8,235 -53% $164.53 7,359 28 Jul 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Stock Option (right to buy) Options Exercise $0 -1,250 -100% $0.000000* 0 28 Jul 2023 Class A common stock 1,250 $92.20 Direct F3
transaction RETA Stock Option (right to buy) Options Exercise $0 -6,666 -67% $0.000000 3,334 28 Jul 2023 Class A common stock 6,666 $92.20 Direct F4
transaction RETA Stock Option (right to buy) Options Exercise $0 -319 -100% $0.000000* 0 28 Jul 2023 Class A common stock 319 $92.20 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $164.25 to $164.69. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The options vested on July 15, 2021.
F4 The options vest in three equal yearly installments through April 15, 2024, subject to continued service through each vesting date.
F5 The options vested on July 15, 2021.